These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 31233177)

  • 21. Prurigo nodularis and Hashimoto thyroiditis.
    Rishi R; Ringwala S; Tracy J; Fatteh S
    Ann Allergy Asthma Immunol; 2014 Dec; 113(6):673-4. PubMed ID: 25446192
    [No Abstract]   [Full Text] [Related]  

  • 22. Dupilumab for the treatment of prurigo nodularis: A systematic review.
    Cao P; Xu W; Jiang S; Zhang L
    Front Immunol; 2023; 14():1092685. PubMed ID: 36742321
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dupixent® (Dupilumab): A Newly Approved Interleukin-4 Receptor Antagonist for the Treatment of Atopic Dermatitis in Pediatric Patients.
    Gupta AK; Love RP; Abramovits W; Vincent KD
    Skinmed; 2019; 17(2):107-109. PubMed ID: 31145061
    [No Abstract]   [Full Text] [Related]  

  • 24. Tape-Strip Proteomic Profiling of Atopic Dermatitis on Dupilumab Identifies Minimally Invasive Biomarkers.
    He H; Olesen CM; Pavel AB; Clausen ML; Wu J; Estrada Y; Zhang N; Agner T; Guttman-Yassky E
    Front Immunol; 2020; 11():1768. PubMed ID: 32849633
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of Dupilumab for the Treatment of Generalized Prurigo Nodularis Phenotype of Adult Atopic Dermatitis.
    Napolitano M; Fabbrocini G; Scalvenzi M; Nisticò SP; Dastoli S; Patruno C
    Dermatitis; 2020; 31(1):81-84. PubMed ID: 31517666
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of dupilumab for chronic prurigo in elderly patients with atopic dermatitis.
    Mitsuyama S; Higuchi T
    An Bras Dermatol; 2023; 98(1):86-89. PubMed ID: 36376117
    [No Abstract]   [Full Text] [Related]  

  • 27. Two Cancer Patients Receiving Dupilumab for Treatment of Atopic Dermatitis.
    Fowler E; Rosen J; Lev-Tov H; Yosipovitch G
    Acta Derm Venereol; 2019 Sep; 99(10):899-900. PubMed ID: 31037315
    [No Abstract]   [Full Text] [Related]  

  • 28. Prurigo nodularis and pembrolizumab: A therapeutic challenge.
    Fattore D; Panariello L; Annunziata MC; Fabbrocini G
    Eur J Cancer; 2019 Mar; 110():8-10. PubMed ID: 30735833
    [No Abstract]   [Full Text] [Related]  

  • 29. Excimer laser vs. clobetasol propionate 0·05% ointment in prurigo form of atopic dermatitis: a randomized controlled trial, a pilot.
    Brenninkmeijer EE; Spuls PI; Lindeboom R; van der Wal AC; Bos JD; Wolkerstorfer A
    Br J Dermatol; 2010 Oct; 163(4):823-31. PubMed ID: 20491772
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Psoriatic Plaques After Initiation of Dupilumab Therapy.
    DeGrazia TM; Raji K; Alshamekh S; Chisolm S
    Dermatitis; 2020; 31(4):e36-e37. PubMed ID: 32665517
    [No Abstract]   [Full Text] [Related]  

  • 31. Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis.
    Ständer S; Yosipovitch G; Legat FJ; Lacour JP; Paul C; Narbutt J; Bieber T; Misery L; Wollenberg A; Reich A; Ahmad F; Piketty C
    N Engl J Med; 2020 Feb; 382(8):706-716. PubMed ID: 32074418
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dupilumab for pediatric prurigo nodularis: A case report.
    Fachler T; Maria Faitataziadou S; Molho-Pessach V
    Pediatr Dermatol; 2021 Jan; 38(1):334-335. PubMed ID: 33247435
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term Remission of Severe and Refractory Chronic Actinic Dermatosis with Dupilumab: A Case Report with Review of the Literature.
    Clélia Vanhaecke ; Manuelle Viguier
    Acta Derm Venereol; 2024 Aug; 104():adv40453. PubMed ID: 39175450
    [No Abstract]   [Full Text] [Related]  

  • 34. Effectiveness and safety of dupilumab for the treatment of prurigo nodularis in a French multicenter adult cohort of 16 patients.
    Calugareanu A; Jachiet M; Tauber M; Nosbaum A; Aubin F; Misery L; Droitcourt C; Barbarot S; Debarbieux S; Saussine A; Bagot M; de Masson A; Sénéschal J; Staumont-Sallé D; Bouaziz JD;
    J Eur Acad Dermatol Venereol; 2020 Feb; 34(2):e74-e76. PubMed ID: 31529718
    [No Abstract]   [Full Text] [Related]  

  • 35. Diagnosis and treatment of actinic prurigo.
    Hojyo-Tomoka MT; Vega-Memije ME; Cortes-Franco R; Domínguez-Soto L
    Dermatol Ther; 2003; 16(1):40-4. PubMed ID: 12919125
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dupilumab for the Treatment of Prurigo Nodularis.
    Alkhaleefa A; Woo TE; Parsons L
    Skin Therapy Lett; 2023 Nov; 28(6):7-9. PubMed ID: 38016088
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prurigo Nodularis Mechanisms and Current Management Options.
    Brown TA; Khachemoune A
    Cutis; 2024 Aug; 114(2):E43-E52. PubMed ID: 39298765
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of thalidomide in the treatment of prurigo nodularis.
    Taefehnorooz H; Truchetet F; Barbaud A; Schmutz JL; Bursztejn AC
    Acta Derm Venereol; 2011 May; 91(3):344-5. PubMed ID: 21279302
    [No Abstract]   [Full Text] [Related]  

  • 39. Dramatic improvement of generalized prurigo nodularis with dupilumab.
    Calugareanu A; Jachiet M; Lepelletier C; De Masson A; Rybojad M; Bagot M; Bouaziz JD
    J Eur Acad Dermatol Venereol; 2019 Aug; 33(8):e303-e304. PubMed ID: 30893496
    [No Abstract]   [Full Text] [Related]  

  • 40. Dupilumab Treatment for Generalized Prurigo Nodularis.
    Beck KM; Yang EJ; Sekhon S; Bhutani T; Liao W
    JAMA Dermatol; 2019 Jan; 155(1):118-120. PubMed ID: 30427994
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.